Flow cytometric detection of minimal residual disease (MRD) in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) requires immunophenotypic discrimination between residual leukaemic cells and B-cell precursors (BCPs) which regenerate during therapy intervals. In this study, EuroFlow-based 8-colour flow cytometry and innovative analysis tools were used to first characterize the immunophenotypic maturation of normal BCPs in bone marrow (BM) from healthy children, resulting in a continuous multiparametric pathway including transition stages. This pathway was subsequently used as a reference to characterize the immunophenotypic maturation of regenerating BCPs in BM from children treated for BCP-ALL. We identified pre-B-I cells that expressed low or dim CD34 levels, in contrast to the classical CD34 high pre-B-I cell immunophenotype.
B-cell precursors (BCPs) differentiate to mature B-cells in bone marrow (BM), mature B-cells being released into peripheral blood (PB). Based on classical immunophenotyping, BCP differentiation has been previously subdivided into (Ghia et al, 1996; Noordzij et al, 2002; van Zelm et al, 2005) . Overall, the percentages of BCPs in BM are highly variable among healthy individuals and decline with age (McKenna et al, 2001; Bras et al, 2013) . B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is a clonal expansion of a malignantly transformed BCP cell. Therapy in BCP-ALL patients targets the malignant cells, but it also affects the remaining normal BCP population. However, normal BCPs are able to regenerate during therapy intervals and after the end of therapy. During BCP regeneration, the BCP population is relatively increased (van Lochem et al, 2000; van Wering et al, 2000; Gaipa et al, 2013) .
To determine treatment response and subsequent prognosis in children treated for BCP-ALL, minimal residual disease (MRD) measurements are currently performed (Conter et al, 2010; Kamps et al, 2010; Mejstrikova et al, 2010) . Flow cytometry is one of the methods used for MRD detection, in which residual leukaemic cells are recognized based on their aberrant immunophenotype (Coustan-Smith et al, 2000; Lucio et al, 2001; Obro et al, 2012; Denys et al, 2013; van Dongen et al, 2015; Karawajew et al, 2015) . Given that the immunophenotype of leukaemic cells resembles that of BCPs, it is particularly difficult to detect residual leukaemic cells during therapy intervals, i.e. when regenerating BCPs are abundantly present (Dworzak et al, 2002; Mirkowska et al, 2013; Sedek et al, 2014) . Leukaemic cells can be discriminated from regenerating BCPs by the expression of BCP-ALL specific markers, by overexpression or underexpression of Bcell differentiation markers or by asynchronous expression of B-cell differentiation markers (Hurwitz et al, 1988; Campana & Coustan-Smith, 1999; Lucio et al, 1999; van Lochem et al, 2004; Szczepanski et al, 2006; Seegmiller et al, 2009; Gaipa et al, 2013) .
In this study, we first aimed to map the immunophenotypic maturation profile of normal BCPs in BM from healthy children. Previous studies on normal B-cell differentiation, using 4-to 6-colour immunostains, provided a consensus model, in which four to five discrete BCP stages could be discerned (Loken et al, 1987; Ghia et al, 1996; McKenna et al, 2001; Noordzij et al, 2002; van Lochem et al, 2004; van Zelm et al, 2005; Sevilla et al, 2009 ). However, BCPs that expressed a combination of differentiation markers and did not fit into any of these stages were observed in BM from healthy individuals (Campana & Janossy, 1988; Dworzak et al, 1997) . These BCPs might represent transition phases between the well-defined BCP stages or parallel, alternative maturation pathways.
Secondly, we aimed to characterize the immunophenotypic maturation of regenerating BCPs in children treated for BCP-ALL, because this will result in a better discrimination between leukaemic cells and regenerating BCPs and, consequently, may improve flow cytometric MRD detection. Most of the previous studies on regenerating BCPs during and after ALL-therapy focused on the relative ratios between the known BCP stages (Dworzak et al, 1997; van Lochem et al, 2000; van Wering et al, 2000; McKenna et al, 2001; Babusikova et al, 2008) . Studies that specifically evaluated the immunophenotypic maturation of regenerating BCPs used 3-colour or 4-colour flow cytometry, which is not sufficient for a detailed analysis (Dworzak et al, 1997; McKenna et al, 2001; Babusikova et al, 2008) .
In this study, we used a single 8-colour immunostain and EuroFlow-based multivariate analysis strategies (Kalina et al, 2012) to visualize the immunophenotypic maturation of normal BCPs in healthy children as a continuous multiparametric pathway, which was subsequently used to characterize the immunophenotypic maturation profile of regenerating BCPs in children treated for BCP-ALL.
Methods

BM samples from healthy children and BCP-ALL patients
Bone marrow was obtained from three healthy children (all male; aged 2, 5 and 13 years old) who were a BM stem cell donor for their siblings, with parental informed consent and with approval of the medical ethical committee of the Leiden University Medical Centre (protocol P08.001). Twenty-eight diagnosis BM samples and 28 follow-up BM samples were collected from paediatric BCP-ALL patients treated according to the Dutch Childhood Oncology Group (DCOG) ALL11-protocol and assigned to the standard risk (SR) treatment group or medium risk (MR) treatment group. The follow-up BM samples were acquired during the interval after induction therapy (at 3 months after start of therapy, n = 10), during the interval after therapy-block M (at 5 months after start of therapy, n = 15) and at 1 year after end of therapy (n = 3) ( Figure S1 ) (van Lochem et al, 2000; van Wering et al, 2000) . All follow-up BM samples were MRD negative at a limit of detection between 10 À4 and 10 À5 , as determined by real-time quantitative polymerase chain reaction analysis of rearranged immunoglobulin and T-cell receptor genes (van der Velden et al, 2007; van der Velden & van Dongen, 2009 Cell surface markers were stained first, followed by staining of intracellular markers using the Fix&Perm reagent kit (An der Grub, Wien, Austria) (Kalina et al, 2012) . At least 1 9 10 6 events were measured per sample on a FACSCanto-II flow cytometer (BD Biosciences) using the FACSDiva software (BD Biosciences). For flow cytometry data analysis, Infinicyt software (Cytognos SL, Salamanca, Spain) was used based on the approaches and tools described in detail in the Results section (Kalina et al, 2012; Pedreira et al, 2013) .
High-speed cell sorting
One normal BM sample and two regenerating BM samples were stained with the same antibodies as described above and by applying the Foxp3/Transcription-Factor-Staining Buffer Set for intracellular staining (resulting in a higher DNA yield than after applying Fix&Perm reagents). One additional BM sample with a very low white blood cell (WBC) count was stained for surface markers only, in order to further optimize DNA yield (intracellular markers were not required in this case due to absence of BCPs beyond the pre-B-I stage). After sorting of the selected BCP fractions (FACSAria-III, BD Biosciences), DNA was extracted using the Mammalian Genomic DNA Miniprep Kit (SigmaAldrich, St. Louis, MO, USA).
GeneScan analysis of IGH gene rearrangements
IGH gene rearrangements from the sorted BCP fractions were amplified with BIOMED2-primers and subsequently analysed with GeneScan as previously described (van Dongen et al, 2003; van Zelm et al, 2005) . The presence of high frequencies of in-frame rearrangements could be deduced from triplet spacing of the GeneScan peaks (van Dongen et al, 2003; van Zelm et al, 2005) .
Statistical methods
The Mann-Whitney U test was used to establish the statistical significance of differences observed between groups for continuous (non-parametric) variables, using the Prism 5.0 software (GraphPad, La Jolla, CA, USA). A P value of less than 0Á05 was considered statistically significant.
Results
Detailed analysis of normal BCP differentiation
We first aimed to evaluate the immunophenotypic maturation of normal CD19 + BCPs. Therefore B-cell populations from three BM samples of healthy children were merged and analysed with the Infinicyt maturation tool (Data S1). This resulted in a multiparametric differentiation pathway consisting of an arbitrary number of 20 immunophenotypic stages of maturation ( Fig 1A) . The expression levels of the individual differentiation markers in each stage were visualized in a maturation diagram ( Fig 1C) . Stages in which the individual differentiation markers showed similar expression levels were then combined, resulting in a total of 7 distinct immunophenotypic stages (Fig 1B) . These 7 maturation stages formed a continuous multiparametric differentiation pathway, in which each stage gradually evolved into the next: Stage 1 BCPs expressed high levels of the early progenitor markers CD34 and CD10, low levels of the mature B-cell marker CD45 and CD20, and positivity for TdT, an enzyme which is only detectable at high levels during IGH gene rearrange- Figure S2 ).
The immunophenotypic maturation of regenerating BCPs differs from that of normal BCPs
We next aimed to evaluate to what extent the immunophenotypic maturation of regenerating BCPs is similar to that of normal BCPs. Therefore, regenerating BM from BCP-ALL patients at 3 months (n = 10) and 5 months (n = 15) after start of therapy and at 1 year after end of therapy (n = 3) were analysed. Principal component analysis was used to immunophenotypically compare regenerating BCPs (present at 3 and 5 months after start of treatment) with normal BCPs based on forward scatter, sideways scatter and all 8 differentiation markers together. After exclusion of Igj/k-positive immature BCPs and mature B-cells (Stage 6 and 7), which were hardly present in regenerating BM, the regenerating BCPs of each patient were visualized in an Automatic Population Separator (APS) plot with a fixed normal BCP maturation pathway (Fig 2) . As expected, BM samples taken at 3 and 5 months after start of therapy showed a shift in distribution towards the pre-B-I subset (also shown in conventional dot plots in Figure S3) . Surprisingly, 80% of the regenerating BM samples taken at 3 months after start of therapy (n = 10) and 87% of the regenerating BM samples taken at 5 months after start of therapy (n = 15) showed an immunophenotypic maturation that deviated from the normal BCP maturation pathway (Fig 2A, B) . In these samples, more than 5% (up to 73%) of the regenerating BCPs were located outside the 2-standard deviation (2SD) boundaries of the normal BCP maturation pathway. All regenerating BCPs outside the 2SD boundaries were, according to the conventional dot plots, cyIgl-negative and TdT-positive. Of note, these cells could not represent pro-B cells, because CD19-negative cells were excluded from this analysis. These results indicated that the cells with an aberrant immunophenotype were probably part of the pre-B-I subset. In contrast, BM samples taken at 1 year after end of therapy showed completely normal immunophenotypic maturation, virtually completely overlapping the normal BCP maturation pathway (Fig 2C) .
The regenerating pre-B-I subset contains a high percentage of CD34 À /dim cells
To evaluate which surface markers caused the regenerating pre-B-I cells to deviate from the normal pre-B-I cells, regenerating pre-B-I cells and normal pre-B-I cells were gated based on cyIglÀTdT+ and compared using unsupervised and balanced principal component (PC) analysis visualized in an APS1 (PC1 vs. PC2) (Fig 3A) . This analysis showed that, out of all of the individual markers, CD34 differed the most between normal and regenerating pre-B-I cells (Fig 3B) . Evaluation of CD34 expression in conventional dot plots showed that the difference in CD34 expression was the result of a significantly higher percentage of CD34
Àdim cells within the pre-B-I subset in regenerating BM at month 3 (median 34%; range 12-85%) and month 5 (median 27%; range 11-80%) than in normal BM (median 10%; range 9-13%) ( Fig 4A+C) . Two additional BM samples from healthy children confirmed low percentages of CD34 Àdim cells within the pre-B-I subset (both <5%; data not shown). In normal BM, the CD34 Àdim pre-B-I cells accounted for less than 2% of the total BCP population, which explains why these cells were not regarded as a separate immunophenotypic stage in the normal BCP maturation pathway described above. The percentage of CD34 Àdim cells within the regenerating pre-B-I subset varied widely between patients, but was unrelated to the cellularity of the BM sample, the total percentage of B-cells in the BM sample and the exact length of the preceding therapy interval, which was very consistent (data not shown). Additionally, also regenerating BM from a patient with central nervous system Non-Hodgkin lymphoma 2 weeks after end of a high-dose methotrexate chemotherapy cycle, showed a high percentage of CD34 Àdim cells within the pre-B-I subset (Fig 4B) . Cell-cycle analysis showed absence of sub-G1 peaks in CD34
Àdim pre-B-I cells from regenerating BM sampleseither at month 3 (n = 5) or month 5 (n = 5) -indicating Àdim pre-B-I cells. Therefore, BCP-ALL populations (n = 26) and the CD34 Àdim pre-B-I cell population (merge of n = 29)
were separated in an APS that only took the expression of cyIgl, TdT and CD34 into account. This analysis showed that, based on these three markers, 6 out of 26 BCP-ALL cases (23%) had a median that overlapped with the CD34 Àdim pre-B-I cells, i.e. they expressed a CD34
Àdim cyIgl À TdT + immunophenotype (Fig 6) .
Discussion
In order to improve discrimination between residual leukaemic cells and the background of BCPs in BM of patients treated for BCP-ALL, we studied the immunophenotypic maturation of normal and regenerating BCPs. Therefore, we designed an 8-colour antibody panel that allowed us to optimally characterize the full immunophenotypic B cell differentiation in a single tube. For this antibody panel, we selected markers that most contribute to the key processes in BCP development, i.e., first, the production of a functional cyIgl chain (which needs TdT), and secondly the production of the light chains (Igj/k) (Ghia et al, 1996) . To further discriminate between the different subsets, we used cell membrane markers previously shown to allow recognition of specific BCP subsets (Noordzij et al, 2002; van Zelm et al, 2005) : CD19 (B-cells beyond the pro-B cell stage), CD34 (pre-B-I cells), CD10 (immature B-cells), CD20 (mature B-cells) and CD45 (increased expression during differentiation). Our analysis of the immunophenotypic maturation of normal BCPs revealed a stage ('Stage 2') in which BCPs were TdT-positive and therefore classically defined as pre-B-I, but in which a small fraction of the BCPs already contained cyIgl. Furthermore, the BCPs in this stage were CD20 dim . These findings are in contrast with the conventional model on human B-cell differentiation, in which all TdT+ BCPs are cyIgl-negative and CD20-negative (Loken et al, 1987; Ghia et al, 1996; McKenna et al, 2001; Noordzij et al, 2002; van Lochem et al, 2004; van Zelm et al, 2005; Sevilla et al, 2009) . However, other studies also observed BCPs with combined expression of TdT, cyIgl and, if studied, CD20 (Campana & Janossy, 1988; Dworzak et al, 1997) . Probably, this stage represents a transition phase between the pre-B-I and pre-B-II-Large cells. Secondly, our analysis showed a stage ('Stage 4') in which BCPs had passed the pre-B-II-Large immunophenotype, but were still Igj/k-negative. Furthermore, the BCPs in this stage gradually lost their CD20 expression. This stage probably represents a transition Together, only by using a single 8-colour tube in combination with multiparametric analyses, we were able to identify the above-described B-cell differentiation subsets. Even more transition phases might become apparent when new multidimensional tools and techniques, such as single-cell mass cytometry, can be used to study B-cell differentiation (Bendall et al, 2011) . Analysis of regenerating BM from children treated for BCP-ALL showed that the subset distribution of the regenerating BCP population (present during therapy intervals at 3 and 5 months after start of therapy) had shifted towards the early maturation stages. This finding was in accordance with previous studies (van Lochem et al, 2000; van Wering et al, 2000) . More surprisingly, by analysing regenerating BM, we identified pre-B-I cells with low or dim CD34 expression. The pre-B-I origin was supported by the presence of complete IGH gene rearrangements, which were not yet selected on in-frame rearrangements. None of the three previous studies on the immunophenotype of BCPs in regenerating BM reported on TdT + BCPs (pre-B-I cells) with low CD34
expression (Dworzak et al, 1997; McKenna et al, 2001; Babusikova et al, 2008) . However, in two of these studies, regenerating BCPs were not directly compared with normal BCPs from healthy individuals (McKenna et al, 2001; Babusikova et al, 2008) . Moreover, only 3-or 4-colour flow cytometry was used (Dworzak et al, 1997; McKenna et al, 2001; Babusikova et al, 2008) . These aspects might explain why the CD34 Àdim pre-B-I cells in regenerating BM were overlooked in these studies. Apparently, multi-colour flow cytometry (at least >4 colours) is necessary to achieve a detailed immunophenotypic characterization of BCPs. Although CD34 Àdim pre-B-I cells were initially not identified within the normal BCP maturation pathway, we were later able to find low numbers of these cells in BM from healthy controls. Finally, our results showed that a significant proportion of the BCP-ALL cases (23%) expressed a CD34 Àdim cyIglÀTdT+ immunophenotype. Previous studies already described BCP-ALL cases that were negative for CD34, while negative for cyIgl or positive for TdT (Hurwitz et al, 1988; Pui et al, 1993) . Given that CD34
Àdim pre-B-I cells show a marker-expression pattern that is asynchronous according to the current B-cell differentiation model, these BCPs can be mistaken for leukaemic cells with a CD34 . Also, because the expression of differentiation markers on BCP-ALL cells overlaps with regenerating BCPs, MRD detection can be more reliable when also based on the expression of BCP-ALL specific markers. Therefore, within the EuroFlow Consortium, new 8-colour antibody panels are currently being developed to optimize the discrimination between BCP-ALL and the background of regenerating BCPs.
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